Development and Retrospective Validation of the Juvenile Spondyloarthritis Disease Activity Index

Objective To develop and validate the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) for use in clinical practice and research. Methods Using modified Delphi consensus techniques, 10 items were selected by participants in the international pediatric rheumatology listserv, the Childhood A...

Full description

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 66; no. 12; pp. 1775 - 1782
Main Authors Weiss, Pamela F., Colbert, Robert A., Xiao, Rui, Feudtner, Chris, Beukelman, Timothy, DeWitt, Esi Morgan, Pagnini, Ilaria, Wright, Tracey B., Wallace, Carol A.
Format Journal Article
LanguageEnglish
Published United States 01.12.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To develop and validate the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) for use in clinical practice and research. Methods Using modified Delphi consensus techniques, 10 items were selected by participants in the international pediatric rheumatology listserv, the Childhood Arthritis and Rheumatology Research Alliance, and the listserv for the pediatric section of the American College of Rheumatology. Validation was performed in a retrospective multicenter cohort of 244 children. Results In total, 106 physicians representing 14 countries completed the initial questionnaire. Completion rates for the subsequent questionnaires were 84%, 75%, and 77% of the original respondents. Ten items exceeded 80% consensus: arthritis, enthesitis, patient pain assessment, inflammatory markers, morning stiffness, clinical sacroiliitis, uveitis, back mobility, and patient and physician assessments of disease activity. After item analysis, 2 items were eliminated (patient and physician assessments of disease activity). Factor analysis identified 3 primary domains that explained 58% of the variance: peripheral disease, axial disease, and uveitis. The Cronbach's α coefficient was 0.66. The JSpADA had high or moderate correlations with the Juvenile Arthritis Disease Activity Score (r = 0.81), patient and physician assessments of disease activity (r = 0.70 and r = 0.66, respectively), and the Childhood Health Assessment Questionnaire (r = 0.56). The JSpADA discriminated well between subjects with active versus inactive disease (P < 0.001) and was responsive to improvement or worsening in disease activity over time (P < 0.001). Conclusion Using international input and consensus formation techniques, we developed and validated the first disease activity assessment for juvenile spondyloarthritis. Future studies should validate the JSpADA in a prospective multicenter cohort.
Bibliography:Dr. Beukelman has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Genentech, UCB, and Crescendo Bioscience and (more than $10,000) from Novartis.
Dr. Wallace has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and Amgen and research grants from Amgen and Pfizer.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:2151-464X
2151-4658
2151-4658
DOI:10.1002/acr.22411